Tatsuya Yamashita

16PUBLICATIONS
57CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Nutritional epidemiologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 26, 2025
The SELENOP Polymorphism rs7579 Predicts Hepatic Steatosis in Females With Insulin Resistance in the General Population.

Reina Yamamoto, Yumie Takeshita, Hiroaki Takayama

|Nov 21, 2024
Hepatokine leukocyte cell-derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction-associated steatotic liver disease in the general population.

Keita Suzuki, Hiromasa Tsujiguchi, Akinori Hara

|May 23, 2024
Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy.

Miyabi Miura, Michiko Nishino, Kazunori Kawaguchi

|Mar 08, 2024
Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.

Tatsuya Yamashita, Natsumi Suzuki, Katsuaki Motoyoshi

|Jul 05, 2023
A case of frequent hypoglycemic attacks successfully controlled with capecitabine plus temozolomide and 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with recurrent pancreatic insulinoma.

Takeshi Terashima, Tatsuya Yamashita, Naoki Takemura

|May 13, 2023
Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis.

Tsuyoshi Suda, Hajime Takatori, Takehiro Hayashi

Pageof 3

Frequent Collaborators

5 joint publications

Taro Yamashita

4 joint publications

Kouki Nio

4 joint publications

Masao Honda

3 joint publications

Tsuyoshi Suda